BioAge Labs, Inc. (BIOA) vs Kamada Ltd. (KMDA)

BioAge Labs, Inc. and Kamada Ltd. are both Drug Manufacturers Specialty & Generic companies. Kamada Ltd. is the larger, with a market value of $509.4M against $337.4M — 1.5× the size. BioAge Labs, Inc. has negative trailing earnings, so its P/E is not meaningful; Kamada Ltd. trades at 22.9×. Kamada Ltd. has the higher net margin (11.6% vs −912.3%) and the higher return on invested capital (8.47% vs −118.3%). Across the 17 metrics below, Kamada Ltd. leads on 10 and BioAge Labs, Inc. on 7.

Valuation

Metric BIOA KMDA Drug Manufacturers Specialty & Generic median
P/E n/m 22.95 20.14
P/S 30.53 2.63 2.25
P/B 0.84 1.87 1.90
Price to free cash flow n/m 19.18 16.54
EV/EBITDA 0.00 10.33 12.29
EV/Sales (0.04) 2.32 2.56
Earnings yield (33.76%) 4.36% (2.99%)
Free cash flow yield (76.82%) 5.21% 0.00%

Profitability

Metric BIOA KMDA Drug Manufacturers Specialty & Generic median
Gross margin 100.00% 40.82% 53.94%
Operating margin (1,026.28%) 14.51% 0.00%
Net margin (912.25%) 11.60% 0.00%
Free cash flow margin (2,345.11%) 13.72% 0.00%
Return on equity (28.21%) 8.40% (0.40%)
Return on assets (26.27%) 5.92% (3.32%)
Return on invested capital (118.25%) 8.47% 0.00%

Growth

Metric BIOA KMDA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) — 13.17% 10.01%
EPS growth (last fiscal year) 66.21% 40.00% —
Revenue growth, 5-year CAGR — 6.25% 6.74%
Net income growth, 5-year CAGR — 3.34% 0.00%

Health

Metric BIOA KMDA Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.02 0.05
Current ratio 17.19 4.06 2.31
Net debt to EBITDA 3.01 (1.59) 0.85

Dividend

Metric BIOA KMDA Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio — 0.00 0.00

Size

Metric BIOA KMDA Drug Manufacturers Specialty & Generic median
Market cap 337.35m 509.40m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack